The U.S. will issue a review ruling on the “sunset” double anti-dumping policy for passenger car tires in China before October 9th
Impact of high-risk cytogenetic signatures on clinical outcomes in children and young adult patients receiving CD19-targeted CAR-T therapy
Authoritative experts commented that YESCARTA® was first approved by the FDA for second-line LBCL treatment, a milestone new progress in CAR-T therapy!
Universal CD20 CAR-γδ T cell therapy has been granted Fast Track designation by the US FDA. What are the advantages of γδ T cells?
Industry heavyweight: Boshengji publishes long-term follow-up data of autologous CD7-CAR-T therapy in the treatment of r/r T-ALL/LBL
Prof. Zhitao Ying: The first guideline for CAR-T treatment of hematological malignancies
The overall response rate was 96%, and Mustang Bio announced the latest clinical data on CD20 CAR-T therapy
The data of Nkarta's two CAR-NKs are amazing, and the global market of CAR-NK is continuing to update!
Universal CAR-NKT therapy announces the latest clinical data, still effective in CAR-T therapy for relapsed patients
Fast delivery improves activity and durability, and a new generation of ready-to-use CAR-T therapy is granted orphan drug designation by the FDA
Allogene Generic BCMA CAR-T Therapy Receives FDA Orphan Drug Designation
Nature's universal CAR-T announces preclinical data targeting two hematological malignancies
Express delivery enhances the durability of therapy, and differentiated CAR-T therapy is recognized by the FDA as an advanced therapy for regenerative medicine
CAR-T exploration road focuses on the exploration and practice of CAR-T therapy by clinical scientists
From two weeks to one day, the new bioscaffold can quickly generate CAR-T cells in the body
Kill the whole new car-making force in seconds!
Universal CAR-NK for relapsed/refractory acute myeloid leukemia (AML), 3/5 cases achieved CR
Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR
"Tianjin" pure solar car officially released
Universal "modular" CAR-T: Innovent continues to develop cell therapy